Breaking Finance News

Regeneron Pharmaceuticals Inc. (NDAQ:REGN) target bumped up to $475.00, released a research note earlier today by RBC Capital Markets

Boasting a price of $435.11, Regeneron Pharmaceuticals Inc. (NDAQ:REGN) traded -0.70% lower on the day. With the last stock price close down -1.52% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Regeneron Pharmaceuticals Inc. has recorded a 50-day average of $474.95 and a two hundred day average of $444.94. Volume of trade was down over the average, with 318,067 shares of REGN changing hands under the typical 859,475

RBC Capital Markets raised the target price of Regeneron Pharmaceuticals Inc. (NDAQ:REGN) to $475.00 stating a potential upside of 0.09%.

On 08/17/2017, Evercore ISI released a statement for Regeneron Pharmaceuticals Inc. (NDAQ:REGN) bumped up the target price from $0.00 to $605.00 that suggested an upside of 0.31%.

Performance Chart

Regeneron Pharmaceuticals Inc. (NDAQ:REGN)

With a total market value of $0, Regeneron Pharmaceuticals Inc. has price-earnings ratio of 43.96 with a one year low of $325.35 and a one year high of $543.55 .

A total of 21 equity analysts have released a ratings update on REGN. Eight equity analysts rating the company a strong buy, six equity analysts rating the company a buy, eleven equity analysts rating the company a hold, one equity analyst rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $475.76.

Brief Synopsis About Regeneron Pharmaceuticals Inc. (NDAQ:REGN)

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.